Effect of cisplatin combined with 5-fluorouracil on endocrine Ishikawa cells in endometrial cancer and its possible mechanism
10.3969/j.issn.1005-1678.2016.08.010
- VernacularTitle:顺铂联合5-氟尿嘧啶对子宫内膜癌Ishikawa细胞的影响及其可能机制
- Author:
Liqin WANG
;
Quanxin QU
- Publication Type:Journal Article
- Keywords:
cisplatin;
5-fluorouracil;
endometrial carcinoma;
Ishikawa cells;
apoptosis
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(8):47-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of cisplatin and 5-fluorouracil on endocrine Ishikawa cells in the treatment of endometrial cancer. Methods The human endometrial cancer cell line Ishikawa were selected, at the logarithmic growth period, the cells were divided into three groups of 5-fluorouracil (5 mg/L) group, cisplatin (5 mg/L) group and cisplatin (5 mg/L) combined with fluorouracil (5 mg/L) group ( combined group).After treated with corresponding drugs treatment, the cell viability was detected by MTT, the apoptosis was detected by flow cytometry, and the Bcl-2 and p65 expressions cells were detected by Western blot.Results The inhibitory rate of combined group, cisplatin group and 5-fluorouracil group were (41.45 ± 3.13)%, (25.20 ±3.09)% and (23.19 ±4.10)% respectively, and the inhibitory rate in the combined group was significantly higher than that of the other two groups (P<0.05).The apoptosis rate of the combined group, cisplatin group and 5-group were (29.44 ±4.35)%, (5.74 ±1.12)% and (5.82 ±1.78)% respectively, and the apoptosis rate in the combined group was significantly higher than that of the other two groups (P<0.05).The Bcl-2 relative expression in the combined group, cisplatin group and 5-fluorouracil group were (0.31 ±0.11), (1.23 ±0.49) and (1.28 ±0.59), the p65 expression were (0.67 ±0.23), (1.67 ±0.56) and (1.71 ±0.71), combined group of Bcl-2 and p65 relative expressions were obviously less than that of the other two groups ( P <0.05 ) .Conclusion Cisplatin combined with 5-fluorouracil on endocrine Ishikawa cells in the treatment of endometrial cancer could promote cell apoptosis, inhibit the cell proliferation, and its mechanism may be related to the inhibition of Bcl-2 and p65 protein expressions.
